Association of an activated clotting time ≤250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy)

American Journal of Cardiology

Volumn 91, Issue 8, 2003, Pages 976-978

  Pinto, Duane S ^b   Lorenz, David P ^b   Murphy, Sabina A ^b   Marble, Susan J ^b   DiBattiste, Peter M ^b   Demopoulos, Laura A ^b   Cannon, Christopher P ^b   Gibson, C Michael ^a  

^a TIMI Data Coordinating Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; NITRATE; TIROFIBAN;

ADULT; AGED; ANGINA PECTORIS; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLEEDING; BLOOD CLOTTING TIME; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; CORONARY ARTERY THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT INDICATION;

EID: 0345505222     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00117-6     Document Type: Article

References (18)

1. Ferguson J.J., Dougherty K.G., Gaos C.M., Bush H.S., Marsh K.C., Leachman D.R. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 23:1994;1061-1065.
2. Narins C.R., Hillegass W.B. Jr, Nelson C.L., Tcheng J.E., Harrington R.A., Phillips H.R., Stack R.S., Califf R.M. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 93:1996;667-671.
3. Anonymous. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330:956-961.
4. Anonymous. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
5. Anonymous. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
6. Anonymous. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
7. O'Shea J.C., Hafley G.E., Greenberg S., Hasselblad V., Lorenz T.J., Kitt M.M., Strony J., Tcheng J.E. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention the ESPRIT trial: a randomized controlled trial . JAMA. 285:2001;2468-2473.
8. Popma J.J., Prpic R., Lansky A.J., Piana R. Heparin dosing in patients undergoing coronary intervention. Am J Cardiol. 82:1998;19P-24P.
9. Lincoff A.M. Strategic Approaches in Coronary Intervention. 2000;Lippincott, Williams & Wilkins, Philadelphia.
10. Chew D.P., Bhatt D.L., Lincoff A.M., Moliterno D.J., Brener S.J., Wolski K.E., Topol E.J. Defining the optimal activated clotting time during percutaneous coronary intervention aggregate results from 6 randomized, controlled trials . Circulation. 103:2001;961-966.
11. Cannon C.P., Weintraub W.S., Demopoulos L.A., Robertson D.H., Gormley G.J., Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban rationale and study design of the international TACTICS-TIMI 18 trial . Am J Cardiol. 82:1998;731-736.
12. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., Neumann F.J., Robertson D.H., DeLucca P.T., DiBattiste P.M., Gibson C.M., Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 344:2001;1879-1887.
13. Cannon C.P., McCabe C.H., Wilcox R.G., Langer A., Caspi A., Berink P., Lopez-Sendon J., Toman J., Charlesworth A., Anders R.J., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 102:2000;149-156.
14. Ambrose J.A., Hawkey M., Badimon J.J., Coppola J., Geagea J., Rentrop K.P., Domiguez A., Duvvuri S., Elmquist T., Arias J., Doss R., Dangas G. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol. 86:2000;150-152.
15. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol E.J. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 75:1995;559-562.
16. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., DiBattiste P.M., Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894.
17. Kereiakes D.J., Broderick T.M., Roth E.M., Whang D., Shimshak T., Runyon J.P., Hattemer C., Schneider J., Lacock P., Mueller M., Abbottsmith C.W. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 84:1999;391-395.
18. Anonymous. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-1453.